Market overview
The global prefilled syringe market is worth USD 8.5 bn in 2026 and is forecast to reach USD 19.1 bn by 2036, growing at a 8.5% CAGR. United States is the largest country market and Glass is the largest by material segment.
| Scope | Syringes sold already filled with a drug dose or empty and sterile for pharmaceutical filling, in glass or plastic, with needle, plunger and staked or luer lock tips. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 7.8 bn |
| Value 2026 | USD 8.5 bn |
| Value 2036 | USD 19.1 bn |
| CAGR 2026-2036 | 8.5% |
| Volume 2026 | 7,557 million units |
| Volume 2036 | 16,255 million units |
| Average price 2026 | USD 1.12 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Prefilled Syringe market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 8.5 bn |
| 2027 | USD 9.2 bn |
| 2028 | USD 10.0 bn |
| 2029 | USD 10.8 bn |
| 2030 | USD 11.7 bn |
| 2031 | USD 12.7 bn |
| 2032 | USD 13.8 bn |
| 2033 | USD 15.0 bn |
| 2034 | USD 16.3 bn |
| 2035 | USD 17.6 bn |
| 2036 | USD 19.1 bn |
Prefilled Syringe market segmentation
By material
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Glass | 70.0% | 60.1% | USD 5.9 bn | 6.9% |
| Plastic cyclic olefin | 22.0% | 31.2% | USD 1.9 bn | 12.4% |
| Other and combination | 8.0% | 8.7% | USD 677 mn | 9.4% |
By design
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Fixed needle | 48.0% | 46.8% | USD 4.1 bn | 8.2% |
| Luer lock | 36.0% | 33.5% | USD 3.0 bn | 7.7% |
| Dual chamber and safety | 16.0% | 19.6% | USD 1.4 bn | 10.7% |
By drug type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Biologics and monoclonals | 34.0% | 41.5% | USD 2.9 bn | 10.7% |
| Vaccines | 24.0% | 19.4% | USD 2.0 bn | 6.2% |
| Anticoagulants | 14.0% | 9.4% | USD 1.2 bn | 4.2% |
| Insulin and GLP-1 | 18.0% | 20.1% | USD 1.5 bn | 9.7% |
| Ophthalmic and other | 10.0% | 9.7% | USD 846 mn | 8.2% |
By capacity
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Up to 1 ml | 46.0% | 42.0% | USD 3.9 bn | 7.5% |
| 1 to 2.25 ml | 38.0% | 40.0% | USD 3.2 bn | 9.1% |
| Above 2.25 ml | 16.0% | 18.0% | USD 1.4 bn | 9.8% |
By closure
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Rigid needle shield | 42.0% | 38.0% | USD 3.6 bn | 7.4% |
| Staked needle with plunger stopper | 34.0% | 36.0% | USD 2.9 bn | 9.1% |
| Cartridge-style and other | 24.0% | 26.0% | USD 2.0 bn | 9.4% |
Top 25 countries for prefilled syringe by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 85.0% of 2026 revenue and the 25 countries below together hold 95.8%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 3.0 bn | 36.0% | USD 6.9 bn | 8.4% |
| 2 | Germany | USD 762 mn | 9.0% | USD 1.6 bn | 7.5% |
| 3 | China | USD 762 mn | 9.0% | USD 2.2 bn | 11.4% |
| 4 | Japan | USD 592 mn | 7.0% | USD 1.1 bn | 6.5% |
| 5 | France | USD 508 mn | 6.0% | USD 1.0 bn | 7.4% |
| 6 | United Kingdom | USD 339 mn | 4.0% | USD 727 mn | 7.9% |
| 7 | Italy | USD 339 mn | 4.0% | USD 689 mn | 7.4% |
| 8 | India | USD 296 mn | 3.5% | USD 918 mn | 12.0% |
| 9 | Switzerland | USD 296 mn | 3.5% | USD 631 mn | 7.9% |
| 10 | Spain | USD 254 mn | 3.0% | USD 517 mn | 7.4% |
| 11 | Netherlands | USD 203 mn | 2.4% | USD 425 mn | 7.7% |
| 12 | Canada | USD 121 mn | 1.4% | USD 253 mn | 7.6% |
| 13 | Australia | USD 89 mn | 1.1% | USD 188 mn | 7.8% |
| 14 | South Korea | USD 72 mn | 0.8% | USD 151 mn | 7.7% |
| 15 | Belgium | USD 61 mn | 0.7% | USD 128 mn | 7.7% |
| 16 | Mexico | USD 53 mn | 0.6% | USD 157 mn | 11.4% |
| 17 | Ireland | USD 47 mn | 0.6% | USD 100 mn | 7.7% |
| 18 | Turkey | USD 43 mn | 0.5% | USD 126 mn | 11.3% |
| 19 | Poland | USD 39 mn | 0.5% | USD 117 mn | 11.6% |
| 20 | Russia | USD 36 mn | 0.4% | USD 77 mn | 7.7% |
| 21 | Sweden | USD 34 mn | 0.4% | USD 71 mn | 7.7% |
| 22 | Brazil | USD 31 mn | 0.4% | USD 94 mn | 11.6% |
| 23 | Singapore | USD 30 mn | 0.3% | USD 88 mn | 11.5% |
| 24 | Denmark | USD 28 mn | 0.3% | USD 59 mn | 7.8% |
| 25 | Indonesia | USD 27 mn | 0.3% | USD 78 mn | 11.2% |
| Rest of world | USD 355 mn | 4.2% | USD 741 mn | 7.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Becton Dickinson
- Gerresheimer
- SCHOTT Pharma
- Stevanato Group
- West Pharmaceutical Services
Group 2: Regional and specialist players
- Nipro
- Terumo
- Ypsomed
- Daikyo Seiko
- Fresenius Kabi
- Taisei Kako
- Medefil
- Vetter Pharma
- Catalent
Group 3: Emerging and niche players
- Shandong Weigao
- SiO2 Materials Science
- Zhejiang Kindly Medical Devices
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the prefilled syringe market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.5% is calculated from the resulting values.
The market is divided by material, by design, by drug type, by capacity, by closure. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the prefilled syringe market?
The global prefilled syringe market is estimated at USD 7.8 bn in 2025 and USD 8.5 bn in 2026.
How fast will the prefilled syringe market grow?
It is forecast to reach USD 19.1 bn by 2036, a compound annual growth rate of 8.5% from 2026, an increase of USD 10.7 bn.
Which country is the largest market for prefilled syringe?
United States is the largest market by revenue at USD 3.0 bn in 2026, 36.0% of the global total. The three largest countries together hold 54.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 12.0% a year from 2026 to 2036.
Which prefilled syringe segment is largest?
In the by material split, Glass is the largest segment with 70.0% of 2026 revenue.
Who are the leading prefilled syringe companies?
Global leaders include Becton Dickinson, Gerresheimer, SCHOTT Pharma, Stevanato Group.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Biomarker DiscoveryUSD 8.7 bn · 11.5% CAGR
- Healthcare Reimbursement OptimizationUSD 8.2 bn · 10.5% CAGR
- Pharmaceutical LabelingUSD 9.0 bn · 5.8% CAGR
- Pharmaceutical ClosureUSD 7.9 bn · 5.6% CAGR
- Digital TherapeuticsUSD 7.9 bn · 20.0% CAGR
- Protein PurificationUSD 9.3 bn · 9.0% CAGR
- Cell TherapyUSD 9.4 bn · 20.0% CAGR
- Transdermal Drug DeliveryUSD 7.6 bn · 6.0% CAGR